King's Patient Safety and Service Quality Research Centre, King's College London, London, UK.
J Eval Clin Pract. 2013 Dec;19(6):1019-25. doi: 10.1111/jep.12013. Epub 2012 Nov 28.
This paper seeks to further explore the question of how best to monitor and govern innovative clinical procedures in their earliest phase of development. We examine the potential value of proposed governance frameworks, such as the IDEAL model, and examine the functioning of a novel procedures review committee.
The paper draws upon 20 qualitative, semi-structured interviews. Nine interviews were conducted with members of a committee that was established as a means of governing innovative procedures within a large National Health Service Foundation Trust hospital in the UK. Eleven interviews were conducted with health providers involved with the development of a variety of novel clinical procedures.
Prominent themes from the data include the potential willingness of clinicians to engage with regulatory frameworks for innovative procedures, existing ways in which clinicians and others attempt to ensure patient's safety and manage uncertainty in the context of novel procedures, views on the potential benefits and drawbacks of engaging with a review committee for novel procedures, and the pragmatic considerations and potential unintended consequences that are entailed in the implementation of regulatory requirements for the monitoring of innovative procedures.
The views of committee members and clinical innovators help us to understand the practical issues of implementing governance structures for novel clinical procedures. The data illustrate those factors that must be taken into account if governance is to support innovation rather than act as an inhibiting factor in the development of new clinical procedures.
本文旨在进一步探讨如何在创新临床程序的早期开发阶段更好地监测和管理这些程序。我们考察了拟议的治理框架(如 IDEAL 模型)的潜在价值,并研究了一个新的程序审查委员会的运作情况。
本文借鉴了 20 次定性、半结构化访谈。其中 9 次访谈是与一个委员会的成员进行的,该委员会是作为英国一家大型国民保健服务基金会信托医院管理创新程序的一种手段而设立的。另外 11 次访谈是与参与各种新临床程序开发的医疗保健提供者进行的。
数据中的突出主题包括临床医生愿意参与创新程序的监管框架的可能性、临床医生和其他人员在新程序背景下试图确保患者安全和管理不确定性的现有方式、对参与新程序审查委员会的潜在利弊的看法、以及在实施创新程序监测的监管要求时所涉及的实际考虑因素和潜在意外后果。
委员会成员和临床创新者的观点帮助我们理解了实施新型临床程序治理结构的实际问题。这些数据说明了如果要使治理支持创新,而不是成为新临床程序发展的抑制因素,就必须考虑到哪些因素。